Zofran Birth Defect MDL Subject Of Oct. 1 Hearing

(August 18, 2015, 2:02 PM EDT) -- WASHINGTON, D.C. — A federal judicial panel on Aug. 14 said it will hear arguments on Oct. 1 on centralizing 12 federal lawsuits in which plaintiffs claim that the prescription nausea drug Zofran causes birth defects (In Re: Zofran [Ondansetron] Products Liability Litigation, MDL Docket No. 2657, JPMDL).

The motion before the Judicial Panel on Multidistrict Litigation was filed July 6 by defendant GlaxoSmithKline LLC (GSK). GSK suggests that an MDL be created in the U.S. District Court for the Eastern District of Pennsylvania and assigned...
To view the full article, register now.